India's drug regulator has banned the manufacture and sale of 35 fixed dose combinations (FDCs), citing concerns over patient ...

Continued treatment with AXS-05, a combination of dextromethorphan and bupropion, significantly reduces the risk for recurrence of Alzheimer’s disease–related agitation, phase 3 results show.

CDSCO asks States and UTs to act upon list of 35 FDCs declared as new drugs: Gireesh Babu, New Delhi Wednesday, April 16, 2025, 08:00 Hrs [IST] The Drugs Controller General of Ind ...

While humans have used opioids for their medicinal benefits, the drug has paved the path of both treatment and tragedy.

NMDA antagonist dextromethorphan is an ingredient found ... However, it has a broader label as unlike J&J's drug it is indicated for use in previously-untreated MDD. Axsome's drug was given ...

Meanwhile, Johnson & Jonson's orexin 2 antagonist seltorexant, Intra-Cellular Therapies' serotonin 5-HT2a antagonist Caplyta (lumateperone), and Relmada Therapeutic' NMDA drug dextromethadone (REL ...

News, April 14, 2025 AAN 2025 Novel Drug Slows Disability Progression ... a combination of dextromethorphan and bupropion, significantly reduces the risk for recurrence of Alzheimer’s disease ...

DayQuil is a combination medication containing acetaminophen, dextromethorphan, and phenylephrine. Both drugs are effective and used to manage pain, fever, and common cold or flu symptoms. However, ...

If you know someone battling depression or Alzheimer’s, Dr. Herriot Tabuteau might just become your new hero. For years, ...

CDSCO bans 35 unapproved Fixed Dose Combinations (FDCs) due to health risks. Immediate halt to production and sale ordered.